Hoth Therapeutics granted Japanese patent for novel RNA-based cancer therapy

Hoth Therapeutics (HOTH) has been granted a key patent by the Japan Patent Office, expanding its global intellectual property portfolio in RNA-based cancer therapeutics. The newly issued patent secures broad claims covering antisense oligomers that target the KIT gene – a clinically validated oncogene associated with gastrointestinal stromal tumors, leukemia, mastocytosis, and other cancers. The KIT gene is implicated in aggressive and difficult-to-treat cancers. Hoth is pioneering a novel RNA-based strategy that could bypass traditional small molecule resistance mechanisms.